Intra-articular injection of the Single shot 6 mL of Hylan G-F 20 (Synvisc)

Drug: Hylan G-F 20

After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.

Other Name: Synvisc

Active Comparator: Corticosteroid (Triamcinolone acetonide)

Intra-articular injection of 1 mL of 40 mg Triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline injected at the knee by single shot

Drug: Corticosteroid

After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.

Other Name: Triamcinolone acetonide

Detailed Description:

Corticosteroid and Hylan G-F 20 are both effective in improving pain and function of osteoarthritic knee patients up to 6 months.

Eligibility

Ages Eligible for Study:

40 Years to 80 Years (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Clinical diagnosis of knee OA

Knee pain for most days of the prior month

Radiographic evidence consistent with knee OA

Aged between 40 and 80 years old

Exclusion Criteria:

Lumbar spondylosis

Gross deformity of the knee

Co-existent inflammatory or crystal arthritis

Prior knee surgery

Injury to the knee in the preceding 6 months

Any intra-articular injection in the preceding 3 months

Pregnant or Lactating

Current infection in the affected knee

Inability to provide informed consent

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01874574